Movement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation

Market Focus06-03

On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.

On the news front, US legislators recently proposed including biotechnology in the scope of the COINS Act, aiming to restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest that domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms. The dual escalation of US-China regulatory barriers has directly undermined the core valuation logic of the sector.

Additionally, Orient Securities previously reduced its holdings in RemeGen by 160,000 shares, while ETF funds have continued to see net outflows for multiple consecutive days. Sector-wide weakness is evident, with AKESO down 3.19%, 3SBIO down 3.68%, Innovent Bio down 2.92%, BeiGene down 2.07%, and SKB Bio down 3.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106162279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 13:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106162279","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation","media":"Market Focus","content":"<p><p>On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.</p><p>On the news front, US legislators recently proposed including biotechnology in the scope of the COINS Act, aiming to restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest that domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms. The dual escalation of US-China regulatory barriers has directly undermined the core valuation logic of the sector.</p><p>Additionally, Orient Securities previously reduced its holdings in RemeGen by 160,000 shares, while ETF funds have continued to see net outflows for multiple consecutive days. Sector-wide weakness is evident, with AKESO down 3.19%, 3SBIO down 3.68%, Innovent Bio down 2.92%, BeiGene down 2.07%, and SKB Bio down 3.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 13:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.</p><p>On the news front, US legislators recently proposed including biotechnology in the scope of the COINS Act, aiming to restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest that domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms. The dual escalation of US-China regulatory barriers has directly undermined the core valuation logic of the sector.</p><p>Additionally, Orient Securities previously reduced its holdings in RemeGen by 160,000 shares, while ETF funds have continued to see net outflows for multiple consecutive days. Sector-wide weakness is evident, with AKESO down 3.19%, 3SBIO down 3.68%, Innovent Bio down 2.92%, BeiGene down 2.07%, and SKB Bio down 3.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1106162279","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106162279","pubTimestamp":1780463322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.On the news front, US legislators recently proposed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动静快讯|RemeGen常规交易跌5.02%，美中生物技术监管壁垒升级施压创新药出站估值","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.On the news front, US legislators recently proposed including biotechnology in the scope of the COINS Act, aiming to restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest that domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms. The dual escalation of US-China regulatory barriers has directly undermined the core valuation logic of the sector.Additionally, Orient Securities previously reduced its holdings in RemeGen by 160,000 shares, while ETF funds have continued to see net outflows for multiple consecutive days. Sector-wide weakness is evident, with AKESO down 3.19%, 3SBIO down 3.68%, Innovent Bio down 2.92%, BeiGene down 2.07%, and SKB Bio down 3.42%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106162279","isCrawlerRequest":true}